Research and Development: Comparing Key Metrics for Ascendis Pharma A/S and Rhythm Pharmaceuticals, Inc.

Biopharma R&D: A Decade of Growth and Innovation

__timestampAscendis Pharma A/SRhythm Pharmaceuticals, Inc.
Wednesday, January 1, 2014196980005280000
Thursday, January 1, 2015405280007148000
Friday, January 1, 20166602200019594000
Sunday, January 1, 20179958900022894000
Monday, January 1, 201814028100050337000
Tuesday, January 1, 2019191621000109450000
Wednesday, January 1, 202026090400090450000
Friday, January 1, 2021295867000104128000
Saturday, January 1, 2022379624000108630000
Sunday, January 1, 2023413454000134951000
Monday, January 1, 2024307004000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in Biopharma

In the competitive world of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Ascendis Pharma A/S and Rhythm Pharmaceuticals, Inc. have demonstrated significant commitment to R&D, with Ascendis Pharma A/S increasing its R&D expenses by over 2,000% from 2014 to 2023. This Danish company has consistently outpaced its American counterpart, Rhythm Pharmaceuticals, Inc., whose R&D spending grew by approximately 2,500% during the same period.

Key Insights

Ascendis Pharma A/S's R&D investment peaked in 2023, reaching nearly 4.1 times its 2014 expenditure. Meanwhile, Rhythm Pharmaceuticals, Inc. saw its highest R&D spending in 2023, marking a 25% increase from the previous year. These trends underscore the relentless pursuit of innovation in the biopharma sector, as both companies strive to bring groundbreaking therapies to market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025